The Effect of Insurance Expansions on Smoking Cessation Medication Prescriptions: Evidence from ACA Medicaid Expansions
We explore the effects of recent Medicaid expansions on Medicaid-financed prescriptions for evidence-based smoking cessation medications. We estimate differences-in-differences models using administrative data on the universe of prescription medications sold in retail and online pharmacies for which Medicaid was a third-party payer. Our findings suggest that expansions increased smoking cessation prescriptions by 36% with heterogeneity across medication class. We provide evidence that these prescriptions were primarily financed by Medicaid programs and not patients, and that our estimates reflect increases in prescriptions among newly eligible populations and not other populations that enrolled in Medicaid due to Affordable Care Act-related changes. Overall our findings suggest that the recent Medicaid expansions allowed newly insured low-income smokers to access efficacious cessation medications.
You may purchase this paper on-line in .pdf format from SSRN.com ($5) for electronic delivery.
Document Object Identifier (DOI): 10.3386/w23450
Users who downloaded this paper also downloaded* these: